Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
Nuccio A, Viscardi G, Salomone F, Servetto A, Venanzi FM, Riva ST, Oresti S, Ogliari FR, Viganò M, Bulotta A, Cameron R, Esposito A, Hines J, Bianco R, Reni M, Cascone T, Garassino MC, Torri V, Veronesi G, Cinquini M, Ferrara R. Nuccio A, et al. Among authors: garassino mc. Eur J Cancer. 2023 Dec;195:113404. doi: 10.1016/j.ejca.2023.113404. Epub 2023 Oct 26. Eur J Cancer. 2023. PMID: 37948842
Bevacizumab for non-small-cell lung cancer.
Garassino MC, Hollander L, Torri V. Garassino MC, et al. N Engl J Med. 2007 Mar 29;356(13):1373; author reply 1374-5. doi: 10.1056/NEJMc070042. N Engl J Med. 2007. PMID: 17392310 No abstract available.
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, Collovà E, Fatigoni S, Ghidini A, Saggia C, Bareggi C, Rossi A, Farina G, Thatcher N, Blackhall F, Lorigan P, Califano R. Garassino MC, et al. Lung Cancer. 2011 Jun;72(3):378-83. doi: 10.1016/j.lungcan.2010.09.009. Epub 2010 Oct 15. Lung Cancer. 2011. PMID: 20950888 Clinical Trial.
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
Pietrantonio F, Garassino MC, Torri V, de Braud F. Pietrantonio F, et al. Among authors: garassino mc. Ann Oncol. 2012 Oct;23(10):2771-2772. doi: 10.1093/annonc/mds332. Epub 2012 Aug 8. Ann Oncol. 2012. PMID: 22875835 Free article. Clinical Trial. No abstract available.
Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.
Garassino MC, Piva S, La Verde N, Spagnoletti I, Iorno V, Carbone C, Febbraro A, Bianchi A, Bramati A, Moretti A, Ganzinelli M, Marabese M, Gentili M, Torri V, Farina G. Garassino MC, et al. PLoS One. 2013;8(4):e59981. doi: 10.1371/journal.pone.0059981. Epub 2013 Apr 5. PLoS One. 2013. PMID: 23577077 Free PMC article. Clinical Trial.
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists. Garassino MC, et al. Lancet Oncol. 2013 Sep;14(10):981-8. doi: 10.1016/S1470-2045(13)70310-3. Epub 2013 Jul 22. Lancet Oncol. 2013. PMID: 23883922 Clinical Trial.
262 results